Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.

Authors:
Address: Howard Taylor Ricketts Laboratory, Argonne National Laboratory, Argonne, Illinois, USA.
Journal:

Publication:
Free Text: Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.

abstract

Current efforts to develop plague vaccines focus on lcrV, a polypeptide that resides at the tip of type III secretion needles. LcrV-specific antibodies block Yersinia pestis type III injection of Yop effectors into host immune cells, thereby enabling phagocytes to kill the invading pathogen. Earlier work reported that antibodies against Y. pestis LcrV cannot block type III injection by Yersinia enterocolitica strains and suggested that lcrV Polymorphisms may provide for escape from LcrV-mediated plague immunity. We show here that polyclonal or monoclonal antibodies raised against Y. pestis KIM D27 LcrV (LcrV(D27)) bind LcrV from Y. enterocolitica O:9 strain W22703 (LcrV(W22703)) or O:8 strain WA-314 (LcrV(WA-314)) but are otherwise unable to block type III injection by Y. enterocolitica strains. Replacing the lcrV gene on the pCD1 virulence plasmid of Y. pestis KIM D27 with either lcrV(W22703) or lcrV(WA-314) does not affect the ability of plague bacteria to secrete proteins via the type III pathway, to inject Yops into macrophages, or to cause lethal plague infections in mice. LcrV(D27)-specific antibodies blocked type III injection by Y. pestis expressing lcrV(W22703) or lcrV(WA-314) and protected mice against intravenous lethal plague challenge with these strains. Thus, although antibodies raised against LcrV(D27) are unable to block the type III injection of Y. enterocolitica strains, expression of lcrV(W22703) or lcrV(WA-314) in Y. pestis did not allow these strains to escape LcrV-mediated plague protective immunity in the intravenous challenge model.

Related Articles
Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.
Infect Immun. 2005
Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.
Philipovskiy AV, Cowan C, Wulff-Strobel CR, Burnett SH, Kerschen EJ, Cohen DA, Kaplan AM, Straley SC. Infect Immun. 2005 Mar; 73(3):1532-42.
Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.
Clin Vaccine Immunol. 2009
Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.
Noel BL, Lilo S, Capurso D, Hill J, Bliska JB. Clin Vaccine Immunol. 2009 Oct; 16(10):1457-66. Epub 2009 Aug 26.
Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Vaccine. 2008
Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E. Vaccine. 2008 Mar 20; 26(13):1616-25. Epub 2008 Feb 6.
Review Plague vaccines and the molecular basis of immunity against Yersinia pestis.
Hum Vaccin. 2009
Review Plague vaccines and the molecular basis of immunity against Yersinia pestis.
Quenee LE, Schneewind O. Hum Vaccin. 2009 Dec; 5(12):817-23. Epub 2009 Dec 1.
Review Prospects for new plague vaccines.
Expert Rev Vaccines. 2009
Review Prospects for new plague vaccines.
Feodorova VA, Corbel MJ. Expert Rev Vaccines. 2009 Dec; 8(12):1721-38.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.